Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.17, Zacks reports. The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.30 million. Ensysce Biosciences had a negative net margin of 660.96% and a negative return on equity of 598.21%.
Ensysce Biosciences Price Performance
ENSC traded up $0.01 during mid-day trading on Friday, hitting $0.41. The stock had a trading volume of 61,814 shares, compared to its average volume of 668,123. The stock’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.68. The firm has a market capitalization of $3.10 million, a price-to-earnings ratio of -0.11 and a beta of 0.85. Ensysce Biosciences has a 1-year low of $0.36 and a 1-year high of $2.06.
About Ensysce Biosciences
Further Reading
- Five stocks we like better than Ensysce Biosciences
- What is the S&P/TSX Index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- The Significance of Brokerage Rankings in Stock Selection
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.